This is an emerging therapeutic technique that works by targeting the underlying causes of a disease, rather than the symptoms it causes. It does this by targeting a particular gene, and preventing it from making the protein that it produces.
The United Kingdom’s NHS has very recently approved a new cholesterol-lowering jab which will be offered to 300,000 people over the next three years.
The drug – inclisiran – will be administered twice a year as an injection.
It will mainly be prescribed to patients who suffer with a genetic condition that leads to high cholesterol, those who have already suffered a heart attack or stroke, or those who haven’t responded well to other cholesterol-lowering drugs, such as statins.
Comments are closed.